Paraneoplastic Endocrine Syndromes

Paraneoplastic Endocrine Syndromes is a topic covered in the Harrison's Manual of Medicine.

To view the entire topic, please or purchase a subscription.

Harrison’s Manual of Medicine 19th edition provides 600+ internal medicine topics in a rapid-access format. Download Harrison’s App to iPhone, iPad, and Android smartphone and tablet. Explore these free sample topics:

Harrison’s Manual of Medicine - App + Web

-- The first section of this topic is shown below --

Both benign and malignant tumors of nonendocrine tissue can secrete a variety of hormones, principally peptide hormones, and many tumors produce more than one hormone (Table 76-1). At the clinical level, ectopic hormone production is important for two reasons.

Paraneoplastic SyndromeEctopic HormoneTypical Tumor Typesa
Hypercalcemia of malignancyPTHrPSquamous cell (head and neck, lung, skin), breast, genitourinary, gastrointestinal
 1,25 dihydroxyvitamin DLymphomas
 PTH (rare)Lung, ovary
 PGE2 (rare)Renal, lung
SIADHVasopressinLung (squamous, small cell), gastrointestinal, genitourinary, ovary
Cushing’s syndromeACTHLung (small cell, bronchial carcinoid, adenocarcinoma, squamous), thymus, pancreatic islet, medullary thyroid carcinoma
 CRH (rare)Pancreatic islet, carcinoid, lung, prostate
 Ectopic expression of GIP, LH/hCG, other G protein–coupled receptors (rare)Macronodular adrenal hyperplasia
Less common
Nonislet cell hypoglycemiaIGF-IIMesenchymal tumors, sarcomas, adrenal, hepatic, gastrointestinal, kidney, prostate
 Insulin (rare)Cervix (small cell carcinoma)
Male feminizationhCGbTestis (embryonal, seminomas), germinomas, choriocarcinoma, lung, hepatic, pancreatic islet
Diarrhea or intestinal hypermotilityCalcitonincLung, colon, breast, medullary thyroid carcinoma
 VIPPancreas, pheochromocytoma, esophagus
Oncogenic osteomalaciaPhosphatonin (FGF23)Hemangiopericytomas, osteoblastomas, fibromas, sarcomas, giant cell tumors, prostate, lung
AcromegalyGHRHPancreatic islet, bronchial and other carcinoids
 GHLung, pancreatic islet
HyperthyroidismTSHHydatidiform mole, embryonal tumors, struma ovarii
HypertensionReninJuxtaglomerular tumors, kidney, lung, pancreas, ovary
aOnly the most common tumor types are listed. For most ectopic hormone syndromes, an extensive list of tumors has been reported to produce one or more hormones.
bhCG is produced eutopically by trophoblastic tumors. Certain tumors produce disproportionate amounts of the hCG α or hCG β subunit. High levels of hCG rarely cause hyperthyroidism because of weak binding to the TSH receptor.
cCalcitonin is produced eutopically by medullary thyroid carcinoma and is used as a tumor marker.
Abbreviations: ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone; FGF23, fibroblast growth factor 23; GH, growth hormone; GHRH, Growth hormone–releasing hormone; GIP, gastric inhibitory peptide; hCG, human chorionic gonadotropin; IGF, insulin-like growth factor; LH, luteinizing hormone; PGE2, prostaglandin E2; PTH, parathyroid hormone; PTHrP, parathyroid hormone–related protein; SIADH, syndrome of inappropriate antidiuretic hormone secretion; TSH, thyroid-stimulating hormone; VIP, vasoactive intestinal peptide.

First, endocrine syndromes that result may either be the presenting manifestations of the neoplasm or occur late in the course. The endocrine manifestations in some instances are of greater significance than the tumor itself, as in pts with benign or slowly growing malignancies that secrete corticotropin-releasing hormone and cause fulminant Cushing’s syndrome. The frequency with which ectopic hormone production is recognized varies with the criteria used for diagnosis. The most common syndromes of clinical import are those of adrenocorticotropic hormone (ACTH) hypersecretion, hypercalcemia, and hypoglycemia. Indeed, ectopic ACTH secretion is responsible for 15–20% of pts with Cushing’s syndrome, and ~50% of pts with persistent hypercalcemia have a malignancy rather than hyperparathyroidism. Because of the rapidity of development of hormone secretion in some rapidly growing tumors, diagnosis may require a high index of suspicion, and hormone levels may be elevated out of proportion to the manifestations.

Second, ectopic hormones serve as valuable peripheral markers for neoplasia. Because of the broad spectrum of ectopic hormone secretion, screening measurements of plasma hormone levels for diagnostic purposes are not cost effective. However, in pts with malignancies that are known to secrete hormones, serial measurements of circulating hormone levels can serve as markers for completeness of tumor excision and for effectiveness of radiation therapy or chemotherapy. Likewise, tumor recurrence may be heralded by reappearance of elevated plasma hormone levels before mass effects of the tumor are evident. However, some tumors at recurrence do not secrete hormones, so hormone measurements cannot be relied on as the sole evidence of tumor activity.

-- To view the remaining sections of this topic, please or purchase a subscription --


* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Paraneoplastic Endocrine Syndromes ID - 623218 Y1 - 2017 PB - Harrison's Manual of Medicine UR - ER -